Also trades as: RPHCF (OTC) · $vol 0M
4527.T JPX
Rohto Pharmaceutical Co.,Ltd.
1W: -0.3%
1M: -8.7%
3M: +16.8%
YTD: +8.0%
1Y: +13.1%
3Y: -4.3%
5Y: +93.7%
¥2,708.00 ($17.13)
-80.00 (-2.87%)
Weekly Expected Move ±3.2%
¥2609
¥2699
¥2788
¥2877
¥2967
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$485.8B
+15.1% ▲
5Y CAGR: +16.6%
Total Liabilities
$165.6B
+10.1% ▲
5Y CAGR: +19.1%
Shareholders Equity
$301.8B
+16.0% ▲
5Y CAGR: +14.1%
Cash & Investments
$86.8B
+12.5% ▲
5Y CAGR: +10.4%
Total Debt
$60.2B
-1.6% ▼
5Y CAGR: +49.4%
Net Debt
-$26.6B
-66.8% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $72.8B | $80.0B | $89.2B | $77.2B | $86.8B |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 |
| Cash & ST Investments | $72.8B | $80.0B | $89.2B | $77.2B | $86.8B |
| Net Receivables | $51.7B | $60.7B | $69.1B | $69.9B | $76.8B |
| Inventory | $33.5B | $41.1B | $46.7B | $61.6B | $65.7B |
| Other Current Assets | $6.3B | $8.6B | $9.8B | $9.3B | $9.9B |
| Total Current Assets | $164.3B | $190.2B | $214.8B | $217.9B | $239.3B |
| Property, Plant & Equip. | $62.8B | $66.2B | $68.6B | $90.5B | $93.0B |
| Goodwill & Intangibles | $9.3B | $9.6B | $9.2B | $56.1B | $83.9B |
| Long-Term Investments | $27.5B | $32.6B | $43.7B | $46.4B | $55.9B |
| Other Non-Current Assets | $5.4B | $5.7B | $6.0B | $7.1B | $9.5B |
| Total Non-Current Assets | $110.3B | $119.4B | $131.4B | $204.0B | $246.5B |
| Total Assets | $274.6B | $309.7B | $346.2B | $421.9B | $485.8B |
| — Liabilities — | |||||
| Accounts Payable | $16.3B | $18.7B | $21.1B | $22.1B | $22.6B |
| Short-Term Debt | $8.0B | $4.2B | $5.3B | $10.9B | $24.7B |
| Deferred Revenue | $22.5B | $30.6B | $5.1B | $0 | $0 |
| Other Current Liabilities | $5.3B | $2.3B | $24.8B | $51.5B | $59.2B |
| Total Current Liabilities | $71.5B | $80.2B | $87.1B | $94.6B | $117.3B |
| Long-Term Debt | $13.3B | $7.5B | $5.2B | $43.2B | $28.2B |
| Other Non-Current Liab. | $1.0B | $2.6B | $2.3B | $3.4B | $2.0B |
| Total Non-Current Liabilities | $19.3B | $14.4B | $12.1B | $55.8B | $48.2B |
| Total Liabilities | $90.8B | $94.6B | $99.1B | $150.4B | $165.6B |
| — Equity — | |||||
| Common Stock | $6.5B | $6.5B | $6.5B | $6.5B | $6.5B |
| Retained Earnings | $162.2B | $184.0B | $209.4B | $228.4B | $256.6B |
| Accumulated OCI | $8.7B | $18.7B | $30.8B | $35.1B | $48.6B |
| Total Stockholders Equity | $178.3B | $209.6B | $246.3B | $260.1B | $301.8B |
| Total Liabilities & Equity | $274.6B | $309.7B | $346.2B | $421.9B | $485.8B |
| — Key Metrics — | |||||
| Total Debt | $21.4B | $11.7B | $10.5B | $61.2B | $60.2B |
| Net Debt | -$51.4B | -$68.3B | -$78.7B | -$15.9B | -$26.6B |
| Total Investments | $27.5B | $32.6B | $43.7B | $46.4B | $55.9B |